AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,782,997 | -97.7% | 146,628 | -97.7% | 0.00% | -97.6% |
| Q2 2023 | $78,609,699 | +540.2% | 6,258,734 | +465.2% | 0.04% | +500.0% |
| Q1 2023 | $12,279,658 | -3.0% | 1,107,273 | +6.8% | 0.01% | 0.0% |
| Q4 2022 | $12,653,272 | -22.3% | 1,036,304 | -33.6% | 0.01% | -30.0% |
| Q3 2022 | $16,282,000 | -75.9% | 1,559,560 | -75.2% | 0.01% | -73.7% |
| Q2 2022 | $67,571,000 | +26.3% | 6,291,476 | +11.4% | 0.04% | +52.0% |
| Q1 2022 | $53,508,000 | -19.7% | 5,650,177 | -2.1% | 0.02% | -16.7% |
| Q4 2021 | $66,627,000 | -2.0% | 5,768,647 | -19.0% | 0.03% | -6.2% |
| Q3 2021 | $67,971,000 | -15.5% | 7,117,394 | -14.7% | 0.03% | -17.9% |
| Q2 2021 | $80,443,000 | +11.3% | 8,344,730 | +14.1% | 0.04% | 0.0% |
| Q1 2021 | $72,261,000 | -43.2% | 7,313,927 | +32.7% | 0.04% | -50.0% |
| Q4 2020 | $127,309,000 | +50.1% | 5,513,614 | -8.2% | 0.08% | +34.5% |
| Q3 2020 | $84,796,000 | -10.2% | 6,005,452 | -4.1% | 0.06% | -19.4% |
| Q2 2020 | $94,413,000 | +147.9% | 6,260,809 | +51.9% | 0.07% | +111.8% |
| Q1 2020 | $38,080,000 | +140.1% | 4,121,255 | +153.1% | 0.03% | +240.0% |
| Q4 2019 | $15,860,000 | -64.9% | 1,628,632 | -71.1% | 0.01% | -67.7% |
| Q3 2019 | $45,195,000 | -36.7% | 5,635,685 | -1.5% | 0.03% | -26.2% |
| Q2 2019 | $71,413,000 | +108.6% | 5,722,445 | +127.3% | 0.04% | +110.0% |
| Q1 2019 | $34,228,000 | +67.4% | 2,517,067 | +17.9% | 0.02% | +33.3% |
| Q4 2018 | $20,452,000 | -61.8% | 2,135,232 | -51.8% | 0.02% | -6.2% |
| Q3 2018 | $53,551,000 | -5.7% | 4,429,539 | +21.8% | 0.02% | 0.0% |
| Q2 2018 | $56,799,000 | +34.0% | 3,636,491 | +29.0% | 0.02% | -20.0% |
| Q1 2018 | $42,399,000 | +49.2% | 2,819,394 | +42.7% | 0.02% | +11.1% |
| Q4 2017 | $28,420,000 | -18.6% | 1,975,120 | -14.7% | 0.02% | -25.0% |
| Q3 2017 | $34,935,000 | +255.7% | 2,316,788 | +137.5% | 0.02% | +242.9% |
| Q2 2017 | $9,822,000 | +31.2% | 975,607 | -7.1% | 0.01% | +16.7% |
| Q1 2017 | $7,488,000 | +34.0% | 1,050,718 | -6.6% | 0.01% | +50.0% |
| Q4 2016 | $5,588,000 | -44.2% | 1,125,023 | -17.0% | 0.00% | -42.9% |
| Q3 2016 | $10,023,000 | +114.2% | 1,354,827 | +58.0% | 0.01% | +133.3% |
| Q2 2016 | $4,680,000 | +69.2% | 857,628 | +161.9% | 0.00% | +50.0% |
| Q1 2016 | $2,766,000 | -62.9% | 327,427 | -57.4% | 0.00% | -60.0% |
| Q4 2015 | $7,459,000 | -2.0% | 769,252 | +41.3% | 0.01% | -16.7% |
| Q3 2015 | $7,615,000 | +87.4% | 544,498 | +89.5% | 0.01% | +100.0% |
| Q2 2015 | $4,063,000 | -16.1% | 287,268 | -35.5% | 0.00% | 0.0% |
| Q1 2015 | $4,841,000 | +56.4% | 445,147 | +19.6% | 0.00% | +50.0% |
| Q4 2014 | $3,095,000 | +180.6% | 372,171 | +100.5% | 0.00% | +100.0% |
| Q3 2014 | $1,103,000 | +126.5% | 185,658 | +27.0% | 0.00% | – |
| Q2 2014 | $487,000 | +1117.5% | 146,215 | +644.2% | 0.00% | – |
| Q1 2014 | $40,000 | +207.7% | 19,648 | +230.6% | 0.00% | – |
| Q4 2013 | $13,000 | -94.0% | 5,944 | -93.6% | 0.00% | – |
| Q3 2013 | $215,000 | – | 93,142 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |